ВОЗОБНОВЛЕНИЕ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ У БОЛЬНЫХ ИБС ПОСЛЕ ЭПИЗОДА КРОВОТЕЧЕНИЯ
Аннотация
Лечение антитромботическими препаратами является балансированием между риском появления кровоточивости, вплоть до фатального кровотечения, и риском непредотвращенного тромбоза. В случае состоявшегося кровотечения проблемы сохранения баланса гемостаза многократно возрастают, что требует от врача четкого понимания и предвидения развития возможных осложнений. Полный отказ от антитромботической терапии (АТТ) сразу после кровотечения может привести к реальной угрозе тромбоза через несколько дней после отмены. Обсуждена тактика возобновления АТТ у больных ИБС после кровотечения: приведены основные классификации кровотечений, применяемые при сердечно-сосудистых заболеваниях (ССЗ), разобраны шкалы риска кровотечений и тромбоза в свете последних (ноябрь 2016 г.) рекомендаций экспертов Европейского общества кардиологов (ЕОК).
Об авторах
А. Б. Сумароков
Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава России,
Россия
Россия
к.м.н.
Ю. В. Доценко
Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава России,
Россия
Россия
к.м.н.
Список литературы
1. Roy T, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TLP, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waxman R Impact of Nuisanse” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. Am J Cardiol, 2008, 102 (12): 1614–1617.
2. Сумароков А.Б., Бурячковская Л.И., Учитель И.А. Кровотечения у больных ишемической болезнью сердца при проведении терапии антиагрегантами. CardioСоматика, 2011, 2(3): 29–34.
3. Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonsales MA, Gaglia M A Jr, Xue Z, Kaneshige K, Satler LF, Kent KM, Pichard AD, Waxman R. Incidence, correlates and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J, 2010, 159: 871-875.
4. Ducrocq G, Wallace J, Baron G, Ravard Ph, Alberts MJ, Wilson PWF, Ohman EM, Brennan DM, D`Agostino RB, Bhatt DL, Steg PhG on behalf of the REACH Investigators, Risk score to predict serious bleeding in stable outpatients with or risk of atherothrombosis. Eur Heart J, 2010, 31: 1257-1265.
5. Rao SV, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial phase-I: hemorrhagic manifestations and changes in plasma fibrino-gen system and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. JACC, 1988, 11(1): 1-11.
6. GUSTO Investigators. An international rand-omized trial comparing four thrombolytic strategies for acute myocardial infarction. NEJM, 1993, 329(10): 673-682.
7. Serebruany VL, Atar D. Assesment of blleding events in clinical trials – proposed of a new classification. Am J Cardiol, 2007, 99(2): 288-290.
8. Rao SV, Eikelboom J, Steg G, Lincoff AM, Weintraub WS, Bassand J-P, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charrigo R, Lee KL, Moscucci M, Harrington RA, on behalf of the Academic Bleeding Consensus Multidisciplinary Working Group, Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A prorosal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. Am Heart J, 2009, 158: 881-886.
9. Mehran R, Rao SV, Bhatt DL, GibsonCM, Caixeta A, Eikelboom J, Kaul S, Wiwiott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials a consensus report from the bleeding academic research consortium. Circulation, 2011, 123(23): 2736-2747.
10. Forest JA, Finlayson ND, Shearman DJ, Endoscopy in gastrointestinal bleeding. Lancet, 1974, 2: 394-397.
11. Waxman R, Definition, Incidence, Correlates and Clinical Impact of “Nuisance” bleeding in Patients Undergoing Drug-Eluting Stent Implantation. Am J Cardiol, 2009, 104(4): 30-33.
12. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Mayor Bleeding in patients With Atrial Fibrillation: The Euro Heart Survey. Chest, 2010, 138(5): 1093-1100.
13. Subherwal S, Bach R, Chen A et al. Baseline Risk of Major Bleeding in Non ST-Segment Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early Implementation of the ACC/AHA guidelines) Bleeding Score. Circulation, 2009, 119: 1873-1882.
14. Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL, Weiss ThW, Collet J-P, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheught FWA, Lanas A, Salman R, Steg PG, Huber K on behalf of ESC Working Group on Thrombosis, Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J, 2016, 11: 1-11.
15. Levine GN (Chair) et al. 2016 ACCF/AHA/SCAI Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practical Guidelines. JACC, 2016, 68(10): 1082-1115.
16. Veich AM, Vanbiervliet G, Gershlick AH, Boustiere Ch, Baglin TP, Smith L-A, Radaelly F, Knight E, Gralnek IM, Hassan C, Dumonceau J-M, Endoscopy in patients on antiplatelet therapy, including oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endosopy, 2016, 48: 1-18.
17. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VKS, Wong VWS, Chan FKL. Continuation of low dose aspirin therapy in peptic ulcers bleeding. A randomized trial. Ann Intern Med, 2010, 152(1): 1-9.
18. Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Growther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta - analysis. Thromb Haemostasis, 2015, 114: 819-825.
19. Staerk L, Lip GYH, Olesen JB, Fosbol EL, Pallisgaarg JL, Bonde AN, Gunlund A, Lindhardt TB, Hansen ML, Torp-Petersen C, Gislason GH. Stroke and recurrent haemorrage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 2015, 351: 5876.
20. Qureshi W, Mittal S, Patsias I, Garicapati K, Kuchiridi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F. Restarting anticoagulation and outcomes after mayor gastrointestinal bleeding in atrial fibrillation. Am J Cardiol, 2014, 113(4): 662-668.
21. Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedual period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol, 2010, 33(4): 385-388.
Рецензия
Для цитирования:
Сумароков А.Б., Доценко Ю.В. ВОЗОБНОВЛЕНИЕ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ У БОЛЬНЫХ ИБС ПОСЛЕ ЭПИЗОДА КРОВОТЕЧЕНИЯ. Медицинский Совет. 2017;(12):138-143. https://doi.org/10.21518/2079-701X-2017-12-138-143
For citation:
Sumarokov A.B., Dotsenko Y.V. RESTORATION OF ANTITHROMBOTIC THERAPY IN IBS PATIENTS AFTER EPISODE OF BLEEDING. Meditsinskiy sovet = Medical Council. 2017;(12):138-143. (In Russ.) https://doi.org/10.21518/2079-701X-2017-12-138-143
Просмотров: 414
Послать статью по эл. почте 